FDA bans Charlotte’s Web CBD as a dietary supplement


By Emily Field (August 11, 2021, 9:17 p.m. EDT) – The United States Food and Drug Administration on Wednesday issued a letter to prominent cannabis company Charlotte’s Web saying it cannot put a product made with it. cannabidiol on the market as a dietary supplement. , noting that CBD reform may have to wait for congressional action.

The agency told Charlotte’s Web it would not approve its application to market its “full spectrum hemp extract” because CBD is already the active ingredient in the treatment of epilepsy from the company, Epidiolex. , the first and so far the only cannabis derivative approved by the FDA. drug, according to the letter dated July 21. This is the position of the FDA since the 2018 farm …

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
  • Create personalized alerts for specific case articles and topics and more!

TRY LAW360 FREE FOR SEVEN DAYS


Source link

Previous Total health starts with a healthy gut
Next FDA balks at application of CBD dietary supplement, maintaining regulatory uncertainty

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *